Key facts
- It has raised $40.0M; the latest was Early Stage VC ($40.0M) in Jul 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Motex
- ·The full record, as it builds
Funding rounds
No funding rounds for Motex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Motex
Developer of targeted RNA delivery technology designed for cell-specific transport beyond the liver. The company's platform uses a modular, scalable lipid nanoparticle system that operates without chemical conjugation, featuring a bifunctional binder mechanism that allows rapid, mix-and-go assembly of targeted nanoparticles; enabling the RNA therapeutics market to deliver payloads such as circular RNA to previously inaccessible tissues, with potential applications in autoimmune, hematologic, and neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Website
- motetx.com/
- Ownership
- Privately Held (backing)
Motex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Motex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Motex in its N-PORT filings yet. We sweep new filings monthly.